ADVERTISEMENT

Antimicrobial resistance (AMR): isang nobelang antibiotic na Zosurabalpin (RG6006) ay nagpapakita ng pangako sa mga pre-clinical na pagsubok

Antibiotic pagtutol lalo na ng Gram-negative bacteria ay halos lumikha ng isang krisis tulad ng sitwasyon. Ang nobelang antibiotic na Zosurabalpin (RG6006) ay nagpapakita ng mga pangako. Napag-alaman na mabisa ito laban sa drug-resistant, Gram-negative bacteria na CRAB sa mga pre-clinical na pag-aaral.   

Antimicrobial resistance (AMR), driven mainly by the misuse and overuse of antimicrobials, is one of top public health risk.  

Infections by Gram-negative bacteria are particularly concerning. It is not easy for most of antibiotics to cross both inner and outer membranes present in this category of bacteria to enter the bacterial cells to show bactericidal actions. Also, Gram-negative bacteria have accumulated disproportionately high degree of antibyotiko pagtutol.  

Acinetobacter baumannii is a Gram-negative bacterium. Infection by one of its strains called ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) is hard to treat using available antibiotics. There is an urgent need for an effective antibyotiko against CARB as mortality rate is high (about 40%-60%) which attributed largely to lack of an effective antibyotiko. A progress towards this goal has been reported.  

Scientists have identified a novel class of antibiotics namely, tethered macrocyclic peptides (MCPs) which are active against the Gram –ve bacteria A. baumannii including CARB by blocking transport of bacterial lipopolysaccharide from the inner membrane to the outer membrane.  

Zosurabalpin (RG6006) ay isang antibyotiko candidate belonging to ‘tethered macrocyclic peptides (MCPs)’ class. In pre-kliniko trials involving in vitro studies and in vivo studies on animal models, Zosurabalpin has been found to be effective against drug-resistant isolates of ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) from different regions. It successfully overcame antibyotiko-resistance mechanism of CARB suggesting Zosurabalpin may potensyal.  

Hence, human kliniko trials have been initiated to check for safety and efficacy Zosurabalpin sa paggamot sa mga invasive na impeksyon na dulot ng CRAB.  

*** 

Sanggunian:  

  1. Zampaloni, C., Mattei, P., Bleicher, K. et al. A novel antibyotiko class targeting the lipopolysaccharide transporter. Nature (2024). https://doi.org/10.1038/s41586-023-06873-0 
  2. Hawser S., et al 2023. Activity of the Novel Antibiotic Zosurabalpin (RG6006) against Clinical Acinetobacter Isolates from China, Open Forum Infectious Diseases, Volume 10, Issue Supplement_2, December 2023, ofad500.1754, https://doi.org/10.1093/ofid/ofad500.1754  

*** 

Umesh Prasad
Umesh Prasad
Mamamahayag sa agham | Founder editor, Scientific European magazine

Mag-subscribe sa aming newsletter

Upang mai-update sa lahat ng mga pinakabagong balita, alok at mga espesyal na anunsyo.

Pinakatanyag na Akda

Mga bakunang "Pan-coronavirus": Ang RNA Polymerase ay Lumilitaw bilang Target ng Bakuna

Ang paglaban sa impeksyon sa COVID-19 ay naobserbahan sa kalusugan...

Mga Berdeng Disenyo para Pamahalaan ang Urban Heat

Ang temperatura sa malalaking lungsod ay tumataas dahil sa 'urban...

'Paglipat ng Memory' Mula sa Isang Organismo patungo sa Isa pang Posibilidad?

Ipinapakita ng bagong pag-aaral na posibleng...
- Advertisement -
94,514Mga Tagahangakatulad
47,678Mga tagasunodsundin
1,772Mga tagasunodsundin
30Subscribersumuskribi